ArticleJournal of addiction psychiatry2024
Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty Cases.
Article in Journal of addiction psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Billions Spent, Few Saved: Rethinking National Institutes of Health HEAL Initiative in Light of Dopaminergic Alternatives to the Opioid Trap.International journal of spine surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Background: The present study relates to a method to treat and detoxify patients with substance use disorder (SUD) utilizing a series of nicotinamide adenine dinucleotide (NAD+) and enkephalinase infusions (NADASE) in subjects attending chemical dependency programs. Objective: The primary objective of the current investigation is to provide some additional clinical evidence to show that NAD+ other amino acids including d-phenylalanine, glycine and ananylglutamine dipeptide and Myer's cocktail (B complex) infusions significantly attenuates substance craving behavior and concomitant psychiatric burden sequalae in poly-drug abusers attending both in-patient and out-patient level of care in a number of chemical dependency programs in orange country. Methods: At symmetry approximately 1,000 now performed approximately 1,000 infusions on 900 patients without any serious side effects pointing to the safety of this procedure. The study cohort (n = 50) as a subgroup consisted of highly addicted poly-drug mixed gender and varied ethnic individuals previously resistant to standard treatment with a range of failed treatment attempts from one to ten. Each patient included in this study received a minimum of 7 infusions for an average duration of four weeks. The data includes craving scores, anxiety, depression, and sleep. We utilized likert scales (1 - 10) self-reported responses, accomplished via a counselor to patient structured interview. Results: In summary considering all fifty subjects using wilcoxon signed rank tests and sign tests, we found the following significance comparing the baseline scores to post outcome scores after NAD infusions; craving scores (P = 1.063E-9); anxiety (P = 5.487E-7); and depression (P = 1.763E-4). There was an improvement trend in the number of sleep hours post infusions, it was non-significant (Pre 6.28, and post 7.34). Importantly, urine analysis of a standard panel of illicit drugs of abuse during the course of NAD infusions resulted in a subset of 40 patients tested at midway during infusions 100% of these patients tested negative. Conclusion: These annotated notes serve an important function showing patient to patient similarities and differences and contribute to the emerging literature concerning NAD efficacy in SUD.
Indexed as
Identifiers
39949994PMC11823434What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.